Back to all MindMaze Therapeutics Holding SA press releases
MindMaze Therapeutics Holding SA
- OTCQB:MMTZF
- SIX:MMTX
MindMaze Therapeutics outlines reimbursement strategy across US, Switzerland and UK
Published
At a glance
- Company
- MindMaze Therapeutics Holding SA
- Listings
- OTCQB:MMTZF, SIX:MMTX
- Announcement type
- Operational update
- Published
- Source announcement
- eqs-news.com
| Measure | Figure |
|---|---|
| Completed clinical studies | 27+ completed clinical studies |
| Regulatory clearances | 11 regulatory clearances |
Figures are quoted from this announcement and selected automatically.
FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices
Announcement Summary
MindMaze Therapeutics Holding SA (SIX: MMTX), quoted in the U.S. on OTCQB under RLFTF and RLFTY, outlined its reimbursement strategy.
- The company began evaluating U.S. reimbursement pathways in 2020 and combines U.S. deployment, Swiss evidence generation, and UK engagement.
- CMS Category III reimbursement covers clinician-supervised digital neurorehabilitation, high-frequency therapy at patients’ homes, remote monitoring, therapy adaptation, and outcome tracking.
- The service-based model aligns reimbursement with patient usage, therapy intensity, and clinical oversight rather than hardware alone, allowing providers to extend therapy duration.
- CAT III enables deployment across post-acute, outpatient, and home-based settings while utilization, outcomes, and payer engagement are further evaluated and documented.
- SwissNeuroRehab is a CHF 11.2 million Innosuisse-backed national flagship consortium involving Swiss university hospitals and rehabilitation centers.
In the UK, the company is aligning evidence generation with NICE evaluation frameworks and NHS discussions on clinical effectiveness, system efficiency, scalability, reimbursement, and adoption.
Investor FAQs
MindMaze Therapeutics outlined the evolution of a global reimbursement strategy combining reimbursed deployment in the United States, national evidence-generation programmes in Switzerland and guideline-aligned engagement in the United Kingdom. The company said the approach is intended to support patient access and long-term reimbursement across major healthcare systems.
MindMaze Therapeutics announced the strategy on December 23, 2025. The announcement describes reimbursement activity and evidence-generation programmes covering the United States, Switzerland and the United Kingdom.
MindMaze Therapeutics is a Swiss-based, commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases and brain disorders. Its platform integrates software, sensors and telehealth, with solutions deployed across clinics and home settings, while the company also manages Relief’s preexisting portfolio of clinical and commercial biopharmaceutical assets.
In the United States, MindMaze Therapeutics uses a CMS Category III reimbursement code for home-based digital neurorehabilitation. The code supports clinician-supervised digital neurorehabilitation, high-frequency therapy at patients’ homes, remote monitoring, therapy adaptation, patient engagement, data-driven personalisation and outcome tracking.
The CMS Category III code covers a service-based care model rather than hardware alone, with reimbursement aligned to patient usage, therapy intensity and clinical oversight. It enables continued real-world deployment while utilisation, outcomes and payer engagement are further evaluated and documented.
MindMaze Therapeutics began evaluating and engaging with United States reimbursement pathways for digital neurorehabilitation in 2020. The company said early clinic-to-home deployments at Vibra Healthcare hospitals generated real-world utilisation and outcomes data that supported reimbursement discussions and the establishment of the CMS Category III code.
MindMaze Therapeutics said CMS Category III reimbursement provides a foundation towards potential Category I reimbursement in the future. The company said real-world evidence from programmes such as SwissNeuroRehab and multi-site deployments with hospital partners is designed to support that progression.
In Switzerland, MindMaze Therapeutics participates in SwissNeuroRehab, a CHF 11.2 million Innosuisse-backed national flagship consortium involving Swiss university hospitals and rehabilitation centres. As a technology partner, the company supports deployment and validation of digital neurorehabilitation pathways across institutional and home-based settings to generate clinical and health-economic evidence.
In the United Kingdom, MindMaze Therapeutics is aligning its evidence-generation strategy with NICE evaluation frameworks for digital health technologies. Its engagement focuses on clinical effectiveness, system efficiency and scalability within the NHS, supporting future reimbursement and adoption discussions.
MindMaze Therapeutics reported 27+ completed clinical studies, 11 regulatory clearances across major markets and a data engine processing more than 1.2 billion data points per month. The company said it is using reimbursement history, real-world patient usage and national-scale evidence generation in its approach to reimbursement.
MindMaze Therapeutics said its clinically validated neurotherapeutics have demonstrated medico-economic outcomes across conditions including stroke, Parkinson’s disease and at-risk aging. The company is also expanding its research and development pipeline into multiple sclerosis, spinal cord injury, traumatic brain injury and Alzheimer’s disease.
MindMaze Therapeutics is listed on the SIX Swiss Exchange under the ticker MMTX. Its shares are quoted in the United States on OTCQB under RLFTF and RLFTY.
MindMaze Therapeutics said its forward-looking statements are based on current plans and assumptions and are subject to risks and uncertainties. The company identified business, economic, financial, regulatory and competitive factors, as well as its ability to execute its strategy, as factors that could cause actual results, financial condition, performance or achievements to differ materially from those expressed or implied.
Source announcement
- Company
- MindMaze Therapeutics Holding SA
- Title
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
- Published
- Source site
- eqs-news.com
Read the source announcement on eqs-news.com
FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.
Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.
Read the original press release
Full text as published, unedited.
Loading the original release…